Erratum: Impact of the Β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients (Clinical Pharmacology and Therapeutics (2012) 92 (21-28) Doi: 10.1038/clpt.2012.18);Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 1, 2012, Pages 21-28

  Rau, T ^a   Dungen H D ^b   Edelmann, F ^c   Waagstein, F ^d   Lainscak M ^e   Dimkovic S ^f   Apostolovic S ^g   Neskovic A N ^h   Haverkamp, W ^b   Gelbrich, G ⁱ   Eschenhagen, T ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

^f ZVEZDARA UNIVERSITY MEDICAL CENTER   (Serbia)

^g Clinical Centre of Ni   (Serbia)

^h University Clinical Hospital Zemun   (Serbia)

ⁱ UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BISOPROLOL; CARVEDILOL;

AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART RATE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUS RHYTHM; TREATMENT RESPONSE;

EID: 84862606180     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.98     Document Type: Erratum

References (27)

1. Dickstein, K. et al.; ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart J. 29, 2388-2442 (2008).
2. Hunt, S.A. et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119, e391-e479 (2009).
3. Mason, D.A., Moore, J.D., Green, S.A. & Liggett, S.B. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J. Biol. Chem. 274, 12670-12674 (1999).
4. Tesson, F. et al. Characterization of a unique genetic variant in the beta1-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy. CARDIGENE Group. J. Mol. Cell. Cardiol. 31, 1025-1032 (1999).
5. Joseph, S.S., Lynham, J.A., Grace, A.A., Colledge, W.H. & Kaumann, A.J. Markedly reduced effects of (-)-isoprenaline but not of (-)-CGP12177 and unchanged affinity of beta-blockers at Gly389-beta1-adrenoceptors compared to Arg389-beta1-adrenoceptors. Br. J. Pharmacol. 142, 51-56 (2004).
6. Düngen, H.D. et al.; CIBIS-ELD Investigators, Subproject Multicenter Trials in the Competence Network Heart Failure. Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clin. Res. Cardiol. 97, 578-586 (2008).
7. Düngen, H.D. et al.; CIBIS-ELD investigators and Project Multicentre Trials in the Competence Network Heart Failure. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur. J. Heart Fail. 13, 670-680 (2011).
8. Wisler, J.W. et al. A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc. Natl. Acad. Sci. USA 104, 16657-16662 (2007).
9. Kim, I.M. et al. Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc. Natl. Acad. Sci. USA 105, 14555-14560 (2008).
10. Rajagopal, S., Rajagopal, K. & Lefkowitz, R.J. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat. Rev. Drug Discov. 9, 373-386 (2010).
11. Noma, T. et al. Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J. Clin. Invest. 117, 2445-2458 (2007).
12. Mialet Perez, J. et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat. Med. 9, 1300-1305 (2003).
13. Swift, S.M., Gaume, B.R., Small, K.M., Aronow, B.J. & Liggett, S.B. Differential coupling of Arg- and Gly389 polymorphic forms of the beta1-adrenergic receptor leads to pathogenic cardiac gene regulatory programs. Physiol. Genomics 35, 123-131 (2008).
14. Molenaar, P. et al. Conservation of the cardiostimulant effects of (-)-norepinephrine across Ser49Gly and Gly389Arg beta(1)-adrenergic receptor polymorphisms in human right atrium in vitro. J. Am. Coll. Cardiol. 40, 1275-1282 (2002).
15. Sandilands, A.J., O'Shaughnessy, K.M. & Brown, M.J. Greater inotropic and cyclic AMP responses evoked by noradrenaline through Arg389 beta 1-adrenoceptors versus Gly389 beta 1-adrenoceptors in isolated human atrial myocardium. Br. J. Pharmacol. 138, 386-392 (2003).
16. Liggett, S.B. et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc. Natl. Acad. Sci. USA 103, 11288-11293 (2006).
17. La Rosée, K., Huntgeburth, M., Rosenkranz, S., Böhm, M. & Schnabel, P. The Arg389Gly beta1-adrenoceptor gene polymorphism determines contractile response to catecholamines. Pharmacogenetics 14, 711-716 (2004).
18. Kindermann, M., Seeland, U., Ruhnke, P., Böhm, M. & Maack, C. Functional effects of β1-adrenoceptor polymorphisms on the hemodynamic response to dobutamine with and without β-blocker administration. Clin. Res. Cardiol. 100, 129-137 (2011).
19. Muthumala, A., Drenos, F., Elliott, P.M. & Humphries, S.E. Role of beta adrenergic receptor polymorphisms in heart failure: systematic review and meta-analysis. Eur. J. Heart Fail. 10, 3-13 (2008).
20. Dorn, G.W. 2nd & Liggett, S.B. Pharmacogenomics of beta-adrenergic receptors and their accessory signaling proteins in heart failure. Clin. Transl. Sci. 1, 255-262 (2008).
21. Leineweber, K. & Heusch, G. Beta 1- and beta 2-adrenoceptor polymorphisms and cardiovascular diseases. Br. J. Pharmacol. 158, 61-69 (2009).
22. Khand, A.U., Rankin, A.C., Martin, W., Taylor, J., Gemmell, I. & Cleland, J.G. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J. Am. Coll. Cardiol. 42, 1944-1951 (2003).
23. Konishi, M. et al. Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure. Circ. J. 74, 1127-1134 (2010).
24. Parvez, B. et al. A common β1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. J. Am. Coll. Cardiol. 59, 49-56 (2012).
25. Joglar, J.A. et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am. Heart J. 142, 498-501 (2001).
26. Lechat, P. et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 103, 1428-1433 (2001).
27. van Veldhuisen, D.J. et al.; MERIT-HF Study Group. Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study. Eur. J. Heart Fail. 8, 539-546 (2006).